[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)

Recruiting Phase 1 Interventional Study
Metastatic Lobular Breast Carcinoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 89
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Diagnostic
Participants needed
30 (estimated)
Sponsor
University of California, Davis · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This is a prospective study using \[68Ga\]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic/advanced invasive lobular breast cancer (LBC).

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * (Ability to understand and willingness to sign a written informed consent document. * Men and women age ≥ 18 yrs * Confirmed presence of metastatic/advanced invasive lobular breast cancer and measurable disease per RECIST (version 1.1) or PERCIST * Available archival tumor tis…
Contacts

Julie Sutcliffe, PhD

916-734-5536

jlsutcliffe@ucdavis.edu

CONTACT